8169 related articles for article (PubMed ID: 2462747)
1. Systemic chemotherapy for metastatic melanoma.
Mc Clay EF; Mastrangelo MJ
Semin Oncol; 1988 Dec; 15(6):569-77. PubMed ID: 2462747
[TBL] [Abstract][Full Text] [Related]
2. Systemic therapy in melanoma.
Nathan FE; Mastrangelo MJ
Semin Surg Oncol; 1998 Jun; 14(4):319-27. PubMed ID: 9588725
[TBL] [Abstract][Full Text] [Related]
3. Current therapy for malignant melanoma.
Legha SS
Semin Oncol; 1989 Feb; 16(1 Suppl 1):34-44. PubMed ID: 2465575
[TBL] [Abstract][Full Text] [Related]
4. The treatment of metastatic melanoma with chemotherapy and biologics.
Atkins MB
Curr Opin Oncol; 1997 Mar; 9(2):205-13. PubMed ID: 9161801
[TBL] [Abstract][Full Text] [Related]
5. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
6. The treatment of disseminated malignant melanoma with special reference to the role of interferons, vinca alkaloids and tamoxifen.
Bezwoda WR
Cancer Treat Rev; 1997 Jan; 23(1):17-34. PubMed ID: 9189179
[TBL] [Abstract][Full Text] [Related]
7. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
8. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
Keilholz U; Goey SH; Punt CJ; Proebstle TM; Salzmann R; Scheibenbogen C; Schadendorf D; LiƩnard D; Enk A; Dummer R; Hantich B; Geueke AM; Eggermont AM
J Clin Oncol; 1997 Jul; 15(7):2579-88. PubMed ID: 9215828
[TBL] [Abstract][Full Text] [Related]
9. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
Bajetta E; Di Leo A; Zampino MG; Sertoli MR; Comella G; Barduagni M; Giannotti B; Queirolo P; Tribbia G; Bernengo MG
J Clin Oncol; 1994 Apr; 12(4):806-11. PubMed ID: 8151323
[TBL] [Abstract][Full Text] [Related]
10. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
Flaherty LE
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
[TBL] [Abstract][Full Text] [Related]
11. The role of interferon alfa in the treatment of metastatic melanoma.
Legha SS
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S24-31. PubMed ID: 9122731
[TBL] [Abstract][Full Text] [Related]
12. Systemic treatments for advanced cutaneous melanoma.
Anderson CM; Buzaid AC; Legha SS
Oncology (Williston Park); 1995 Nov; 9(11):1149-58; discussion 1163-4, 1167-8. PubMed ID: 8703684
[TBL] [Abstract][Full Text] [Related]
13. Systemic chemotherapy.
Klimek VM; Wolchok JD; Chapman PB; Houghton AN; Hwu WJ
Clin Plast Surg; 2000 Jul; 27(3):451-61, ix-x. PubMed ID: 10941565
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
Garbe C
Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for stage 4 melanoma: a three-year experience with cisplatin, DTIC, BCNU, and tamoxifen.
Reintgen D; Saba H
Semin Surg Oncol; 1993; 9(3):251-5. PubMed ID: 8516613
[TBL] [Abstract][Full Text] [Related]
16. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Rudolf Z; Strojan P
Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
[TBL] [Abstract][Full Text] [Related]
17. Management of metastatic cutaneous melanoma.
Buzaid AC
Oncology (Williston Park); 2004 Oct; 18(11):1443-50; discussion 1457-9. PubMed ID: 15609471
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma.
Feun L; Marini A; Moffat F; Savaraj N; Hurley J; Mazumder A
Cancer Invest; 2005; 23(1):3-8. PubMed ID: 15779861
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Tan EH; Ang PT
Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]